Atlas Trials

Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers

Clinical trial NCT04403685 · TERMINATED

Trial details

NCT number
NCT04403685
Sponsor
Beneficência Portuguesa de São Paulo
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
COVIDSARS PneumoniaCytokine Release Syndrome
Start date
2020-05-08
Primary completion
2020-07-08
Enrollment
129

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.